Neupulse, a spinout from the University of Nottingham, has recently secured a £500,000 equity investment via the Midlands Engine Investment Fund II, with Mercia Ventures as the appointed fund manager. Founded in 2021 by Professors Stephen and Georgina Jackson, along with Dr Barbara Morera, Neupulse is leading the way in developing a safe, non-drug treatment for managing Tourette’s syndrome symptoms.
The innovative wristband device, designed to stimulate the median nerve in the wrist, has shown promising results in reducing tic frequency by 25% upon initial use and even further after four weeks. With this investment, Neupulse aims to finalize the device’s development, conduct additional trials, and secure regulatory approvals in the UK, Europe, and the USA. This funding, in addition to a previous investment of £2.5 million earlier this year, brings the total raised by the company to nearly £4.5 million.
Paul Cable, CEO of Neupulse, expressed gratitude for the support from Midlands Engine Investment Fund II, highlighting the role of Mercia Ventures as a valuable partner with expertise in new product development and US market entry. Sandy Reid, from Mercia Ventures, underscored the significance of Neupulse’s device as a genuine alternative to current Tourette’s treatments, emphasizing its potential to transform lives.
Overall, this funding marks another step forward for Neupulse in its mission to bring hope to individuals with Tourette’s syndrome through the innovative technology it has developed.
